P2Y12 inhibitor monotherapy after 1–3 months of DAPT was associated with a significantly lower risk of major bleeding compared to DAPT, regardless the presence of CKD, without a benefit in terms of the prevention of major adverse CV events. Here, P2RY12 is linked to chronic kidney disease.